Publications
Detailed Information
The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Jung Min | - |
dc.contributor.author | Lee, Kyu-Hwa | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Lim, Jae-Jun | - |
dc.contributor.author | Yoo, Chul-Gyu | - |
dc.contributor.author | Han, Sung Koo | - |
dc.contributor.author | Kim, Young Whan | - |
dc.contributor.author | Shim, Young-Soo | - |
dc.contributor.author | Lee, Choon-Taek | - |
dc.contributor.author | Yang, Seok-Chul | - |
dc.date.accessioned | 2012-06-26T05:49:49Z | - |
dc.date.available | 2012-06-26T05:49:49Z | - |
dc.date.issued | 2010-09 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE; Vol.26 3; 415-423 | ko_KR |
dc.identifier.issn | 1107-3756 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77441 | - |
dc.description.abstract | Although Clara cell secretory protein (CC-10, CC-16 or uteroglobin, secretoglobin 1A1) has been ascribed anti-inflammatory, immunomodulatory and anti-cancer activity roles in lung diseases including lung cancer, its precise function remains unclear. The objective of the present study was to evaluate the role of CC-10 in the immunomodulation of human monocytes and dendritic cells (DCs). The human lung adenocarcinoma cell line A549, was used to examine PGE2 production after cyclooxygenase (COX) inhibition and adenovirus encoding human CC-10 cDNA (Ad-CC-10) transfection. Type I and II cytokines were measured from peripheral blood mononuclear cells (PBMCs) and DCs which were cultured with tumor supernatant (TSN) or Ad-CC-10 transfected TSN. When PBMCs were cultured with supernatant A549 (tumor supernatant, TSN), the levels of T-cell helper type 1 (Th1) and 2 (Th2) cytokines increased. However. CC-10 inhibited the induction of Th2 cytokines of PBMCs stimulated with TSN. In DCs, TSN inhibited Th1 type cytokines but induced Th2 type. In contrast, TSN treated with either CC-10 or NS398 (COX-2 inhibitor) stimulated Th1 type and inhibited Th2 type without any phenotypic changes. The supernatants generated in the presence of NS-398 or CC-10 prevented tumor-induced inhibition of allogeneic T-cell stimulation. While the level of interleukin (IL)-10 secretion from DC-Ad-CC-10 was decreased, the level of IL-12 secretion was increased by CC-10. Collectively our data suggest that a supernatant of NSCLC causes an imbalance in the immune response of PBMCs and DCs, which is reversed by CC-10. This suggests that CC-10 is a candidate for the development of a new immunotherapy for lung cancer. | ko_KR |
dc.description.sponsorship | Grant support was from Seoul National University Research
Fund 03-2005-0120. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPANDIDOS PUBL LTD | ko_KR |
dc.subject | Clara cell secretory protein | ko_KR |
dc.subject | cyclooxygenase-2 | ko_KR |
dc.subject | immune modulation | ko_KR |
dc.title | The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 윤정민 | - |
dc.contributor.AlternativeAuthor | 이규화 | - |
dc.contributor.AlternativeAuthor | 이상민 | - |
dc.contributor.AlternativeAuthor | 임재준 | - |
dc.contributor.AlternativeAuthor | 양석철 | - |
dc.contributor.AlternativeAuthor | 유철규 | - |
dc.contributor.AlternativeAuthor | 이춘택 | - |
dc.contributor.AlternativeAuthor | 한성구 | - |
dc.contributor.AlternativeAuthor | 심영수 | - |
dc.contributor.AlternativeAuthor | 김영환 | - |
dc.identifier.doi | 10.3892/ijmm_00000481 | - |
dc.citation.journaltitle | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | - |
dc.description.citedreference | Chen JP, 2007, CANCER EPIDEM BIOMAR, V16, P577, DOI 10.1158/1055-9965.EPI-06-0923 | - |
dc.description.citedreference | Yang SC, 2006, CANCER RES, V66, P3205, DOI 10.1158/0008-5472.CAN-05-3619 | - |
dc.description.citedreference | Yoon JM, 2005, LUNG CANCER-J IASLC, V48, P201, DOI 10.1016/j.lungcan.2004.11.005 | - |
dc.description.citedreference | Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666 | - |
dc.description.citedreference | Yang SC, 2004, CLIN CANCER RES, V10, P2891 | - |
dc.description.citedreference | Pockaj BA, 2004, ANN SURG ONCOL, V11, P328, DOI 10.1245/ASO.2004.05.027 | - |
dc.description.citedreference | Kaufman HL, 2004, J CLIN INVEST, V113, P664, DOI 10.1172/JCI200421148 | - |
dc.description.citedreference | Ye Q, 2004, RESPIRATION, V71, P505, DOI 10.1159/000080636 | - |
dc.description.citedreference | Dannenberg AJ, 2003, CANCER CELL, V4, P431 | - |
dc.description.citedreference | Marincola FM, 2003, TRENDS IMMUNOL, V24, P335, DOI 10.1016/S1471-4906(03)00116-9 | - |
dc.description.citedreference | Hicks SM, 2003, TOXICOLOGY, V187, P217, DOI 10.1016/S0300-483X(03)00060-X | - |
dc.description.citedreference | Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3 | - |
dc.description.citedreference | Lee JC, 2003, CANCER GENE THER, V10, P287, DOI 10.1038/sj.cgt.7700569 | - |
dc.description.citedreference | Sharma S, 2003, CLIN CANCER RES, V9, P961 | - |
dc.description.citedreference | Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408 | - |
dc.description.citedreference | Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532 | - |
dc.description.citedreference | Singh-Ranger G, 2002, EUR J SURG ONCOL, V28, P729, DOI 10.1053/ejso.2002.1329 | - |
dc.description.citedreference | Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168 | - |
dc.description.citedreference | Half E, 2002, CANCER RES, V62, P1676 | - |
dc.description.citedreference | Pai R, 2002, NAT MED, V8, P289 | - |
dc.description.citedreference | Harizi H, 2002, J IMMUNOL, V168, P2255 | - |
dc.description.citedreference | Dohadwala M, 2001, J BIOL CHEM, V276, P20809 | - |
dc.description.citedreference | Klug J, 2000, ANN NY ACAD SCI, V923, P348 | - |
dc.description.citedreference | Stolina M, 2000, J IMMUNOL, V164, P361 | - |
dc.description.citedreference | Sharma S, 1999, J IMMUNOL, V163, P5020 | - |
dc.description.citedreference | Goto S, 1999, CANCER IMMUNOL IMMUN, V48, P435 | - |
dc.description.citedreference | Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125 | - |
dc.description.citedreference | Misra N, 1995, IMMUNOL LETT, V48, P123 | - |
dc.description.citedreference | LESUR O, 1995, AM J RESP CRIT CARE, V152, P290 | - |
dc.description.citedreference | ROPER RL, 1994, ADV PROSTAGLANDIN TH, V22, P101 | - |
dc.description.citedreference | PERI A, 1993, J CLIN INVEST, V92, P2099 | - |
dc.description.citedreference | SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321 | - |
dc.description.citedreference | BROERS JLV, 1992, LAB INVEST, V66, P337 | - |
dc.description.citedreference | LEVIN SW, 1986, LIFE SCI, V38, P1813 | - |
dc.description.citedreference | MUKHERJEE DC, 1983, SCIENCE, V219, P989 | - |
dc.description.citedreference | KRISHNAN RS, 1967, SCIENCE, V158, P490 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.